MNK1 and EIF4E are downstream effectors of MEKs in the regulation of the nuclear export of HDM2 mRNA by Phillips, A. & Blaydes, J.P.
MNK1 AND EIF4E ARE DOWNSTREAM EFFECTORS OF MEKs  
IN THE REGULATION OF THE NUCLEAR EXPORT OF HDM2 
mRNA  
 
Anna Phillips1 and Jeremy P. Blaydes1 
 
 
 
1 Somers Cancer Research Building, University of Southampton, MP824 
Southampton General Hospital, Southampton SO16 6YD United Kingdom 
 
 
Corresponding author: Dr Jeremy P. Blaydes  
Phone: +44 (0)2380 794582 
Fax: +44 (0)2380 795152 
Email: jpb1@soton.ac.uk 
 
Key words: p53, MDM2, mRNA export, breast cancer, eIF4E 
Running title: Regulation of HDM2 by eIF4E 
 2
ABSTRACT 
Regulation of the synthesis, function and degradation of HDM2 (Mdm2 in mouse) 
plays a key role in controlling the abundance and activity of the transcription factor 
p53, with consequent implications for the proliferation and survival of normal and 
cancer cells.  We have previously identified the regulation of export of HDM2 mRNA 
from the nucleus as a novel point of control of HDM2 synthesis.  This process is 
dependent on activity of the growth-factor regulated MEK kinases.  Here we provide 
evidence that the eIF4E kinase, MNK1 is a key downstream effector of MEKs in this 
regulatory pathway.  We show that HDM2 mRNA export in breast cancer cells is 
promoted by over-expressed eIF4E in a MEK- and MNK1- dependent manner, and 
inhibition of MNK1 suppresses endogenous HDM2 mRNA export pathways.  This 
MNK1- and eIF4E- dependent HDM2 regulation occurs through sequences in the 
3’UTR of HDM2 mRNA, and consequently HDM2 mRNA transcripts from both the 
constitutive P1 and inducible P2 promoters are regulated by this pathway.  eIF4E is a 
known oncogene that is over-expressed in human tumours, including the majority of 
breast cancers.  This pathway, therefore, may play an important role in the 
dysregulation of HDM2 oncoprotein expression that occurs in many human tumours. 
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HDM2 is a key regulator of p53 function in the cell (Brooks and Gu, 2006; Vogelstein 
et al., 2000).  Domains within the N-terminus and central acidic region of HDM2 
interact directly with p53 to inhibit the interaction of p53 with transcriptional co-
activators, and target it for ubiquitination, export from the nucleus, and degradation 
by the proteasome (Brooks and Gu, 2006; Wallace et al., 2006).  Experimental 
disruption of the p53-HDM2 interaction can be sufficient to induce the activation of 
p53-dependent cell cycle arrest and apoptotic pathways (Blaydes et al., 1997; 
Vassilev et al., 2004).  Multiple stress-response pathways induce p53 activity in cells 
by regulating HDM2 and the HDM2-p53 interaction (Vogelstein et al., 2000; Wahl 
and Carr, 2001).  The rate of HDM2 protein synthesis is critical in determining p53 
function in both normal stress responses and during tumorigenesis; increased HDM2 
expression due to HDM2 gene amplification is associated with some cancers such as 
osteosarcoma (Oliner et al., 1992), and a single nucleotide polymorphism in the 
HDM2 promoter can result in increased HDM2 protein levels and increased 
susceptibility to tumorigenesis (Bond and Levine, 2007).  Whilst HDM2 gene 
amplification is uncommon in most cancers, HDM2 protein levels are frequently 
increased in many common malignancies including breast, prostate, lung, colon and 
melanoma (Onel and Cordon-Cardo, 2004).  We have therefore studied how the 
expression of the human HDM2 gene is regulated at the transcriptional and post-
transcriptional level in normal and cancer cells (Phelps et al., 2003; Phelps et al., 
2005; Phillips et al., 2006a; Phillips et al., 2006b).   
 
HDM2 has two promoters, which generate transcripts with alternate 5’UTRs (exons 1 
or 2), but a common coding region and 3’UTR (exons 3-12).  The P1 promoter is 
constitutively expressed (Phillips et al., 2006a), whereas the P2-promoter is highly 
 4
inducible by p53 (Zauberman et al., 1995).  Growth factor signalling through RAS-
RAF-MEK-ERK can also regulate HDM2 protein synthesis, with readily identifiable 
consequences for cancer cell survival (Ries et al., 2000; Shaulian et al., 1997).  This 
regulation occurs both through transcriptional regulation at the P2-promoter (Phelps et 
al., 2005; Ries et al., 2000) and, as we have discovered recently, control of the export 
of HDM2 mRNA from the nucleus to its sites of translation in the cytoplasm (Phelps 
et al., 2005).  Bulk export of polyadenylated mRNAs through nuclear pores occurs in 
metazoan cells through an evolutionarily pathway involving the TAP/NXF1/Mex67p 
and NXT1/Mtr2p transporter complex (Cullen, 2003; Erkmann and Kutay, 2004).  
However recent studies have demonstrated that certain mRNAs can be organised and 
exported from the nucleus as functionally related groups, or regulons, by RNA 
binding proteins (Culjkovic et al., 2007; Keene, 2003).  Examples of such RNA-
binding proteins in mammalian cells are HuR (Gallouzi and Steitz, 2001) and eIF4E 
(Culjkovic et al., 2006; von der Haar et al., 2004).  This provides the potential for 
gene-selective control of mRNA export, through at present little is known regarding 
how such pathways may be regulated in response to extra-cellular signals.  In order to 
better understand the mechanisms of MEK-dependent HDM2 mRNA nuclear export, 
we have now delineated some of the molecular pathways downstream of MEK which 
are involved in this process. 
 
A recent report identified HDM2 as one of a number of genes that are regulated at the 
level of mRNA export by eIF4E (Culjkovic et al., 2006).  As the ability of eIF4E to 
regulate mRNA export is known to be regulated by its state of phosphorylation 
(Topisirovic et al., 2004), we set out to investigate whether it might be involved in the 
MEK-dependent HDM2 mRNA export we had previously identified in breast cancer 
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cells (Phelps et al., 2005).  Initial characterisation of a panel of breast cancer cell lines 
(data not shown) determined that the T47D line had an approximately 2 fold greater 
ratio of cytoplasmic to total HDM2 mRNA than most cell lines, including MCF-7, 
and therefore we chose to use MCF-7 for experiments aimed at promoting eIF4E-
dependent mRNA export, and T47D for studies of the inhibition of endogenous 
HDM2 mRNA export pathways.  We first established that transient over-expression of 
eIF4E in MCF-7 resulted in an increase in Cyclin D1 (Figure 1a), a protein whose 
mRNA is well-characterised as a target for eIF4E-dependent nuclear export 
(Culjkovic et al., 2005; Rousseau et al., 1996)).  The abundance of HDM2 protein 
also clearly increased with increasing eIF4E.  We then performed an analysis of the 
subcellular distribution of mRNAs in control- and eIF4E- over-expressing MCF-7 
cells to establish whether eIF4E can promote the nuclear export of HDM2 mRNA in 
these cells (Figure 1b).  When eIF4E was over-expressed there were no significant 
changes in the overall abundance of CYCLIN D1 or HDM2 transcripts in total cell 
extracts, however eIF4E caused increases in the cytoplasmic pools of these mRNAs; 
for HDM2-P1 and –P2 transcripts these increases were to 174.4 ± 22.3% and 180.8 ± 
3.6% of controls respectively.  A reduction in the nuclear fraction was also observed, 
though this was rather more modest.  The difference in the relative changes in 
transcript levels between nuclear and cytoplasmic fractions is most likely because a 
high proportion of the HDM2 transcripts are present in the nucleus; in control cells the 
relative abundance of HDM2-P1 and -P2 transcripts in the cytoplasm compared to the 
nucleus was only 15.6 ± 5.4% and 7.4 ± 0.4% respectively. 
 
We then examined the role of kinases involved in the phosphorylation of eIF4E in the 
regulation of nuclear export of HDM2 mRNA.  MEK1 and MEK2 kinases 
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phosphorylate and activate ERK1 and ERK2, which in turn phosphorylate MNK1, an 
eIF4E serine 209 kinase (Mamane et al., 2004; Waskiewicz et al., 1997).  This is a 
key post-translational modification of eIF4E that can enhance its ability to promote 
mRNA transport (Topisirovic et al., 2004).  T47D cells, as well as having a higher 
cytoplasmic to total HDM2 mRNA ratio than MCF-7, also exhibited a higher level 
(169.0 ± 22.6 %, n=4) of constitutive phosphorylation of eIF4E on serine 209 (Figure 
2a), and were therefore used to examine the effect of pharmacological inhibition of 
kinase activity on eIF4E phosphorylation and the subcellular localisation of HDM2 
mRNA.  Inhibition of MEKs with U0126 resulted in decreased eIF4E phosphorylation 
and a reduction in the abundance of HDM2 and Cyclin D1 proteins (Figure 2b).  We 
have already demonstrated that this reduction in HDM2 involves both an inhibition of 
HDM2-P2 promoter activity, and reduced nuclear export of both HDM2 mRNA 
transcripts (Phelps et al., 2005).  ERK1 and ERK2, key enzymes immediately 
downstream of MEKs in the signalling cascade, phosphorylate multiple substrates 
including MNK1.  To examine whether MNK1 activity is required for optimal HDM2 
synthesis, we treated cells with the MNK inhibitor 4-amino-5-(4-fluoroanilino)-
pyrazolo[3,4-d]pyrimidine (CGP57380) (Knauf et al., 2001; Topisirovic et al., 2004) 
(Figure 2b).  Results were similar to those obtained following inhibition of MEKs, the 
inhibitor causing reduced eIF4E phosphorylation at serine 209, and a decrease in 
HDM2 and Cyclin D1 protein abundance.  CGP57380 has recently been shown to 
inhibit MNK2 as well as MNK1, however MNK2 activity is MEK-independent and, 
as U0126 was nearly as effective as CGP57380 at inhibiting eIF4E phosphorylation, it 
can be concluded that the effects of CGP57380 that we observe are likely to be 
primarily due to its activity towards MNK1 (Buxade et al., 2005).  Figure 2c shows 
that inhibition of MNK1 also has similar effects on HDM2 mRNA to those we have 
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previously reported for U1026 (Phelps et al., 2005).  There was an overall reduction 
in expression of HDM2-P1 and –P2 transcripts in total cellular RNA (decrease to 53.3 
± 5.5% and 33.1 ± 4.5% of controls respectively), presumably due to inhibition of 
transcription through an as-yet undefined pathway, and a greater decrease when 
cytoplasmic mRNA was analysed (to 27.6 ± 3.1% and 15.5 ± 1.4% of controls 
respectively) indicating HDM2 mRNA export was also inhibited.  Nuclear HDM2-P1 
and –P2 transcripts were reduced to a lesser extent than in the whole cell fraction (to 
73.7 ± 3.4% and 54.3 ± 4.4% of controls respectively), indicating retention of the 
synthesised HDM2 transcripts in the nucleus. 
 
eIF4E-dependent mRNA export has been shown to be mediated by a structurally 
conserved 4E-sensitivity element present in the 3’UTR of transcripts (Culjkovic et al., 
2005; Culjkovic et al., 2006).  As such an element can be identified in the structure of 
the 3’UTR of HDM2 (Culjkovic et al., 2006), we cloned the HDM2 3’UTR (-15 to 
+2763 relative to the end of the HDM2 coding sequence) 3’ of the luciferase gene in 
the HDM2-P2 promoter reporter construct hdm2luc01 and examined its effects on 
luciferase expression in MCF-7 cells.  We first assayed expression from hdm2luc01 
or hdm2luc01-3’UTR, in the absence or presence of an eIF4E expression vector 
(Figure 3a).  There was a clear increase (to 171.6 ± 15.3 % of control) in relative 
luciferase activity when eIF4E was over-expressed, only when the reporter vector 
contained the HDM2 3’UTR.  This is strong evidence that the HDM2-3’UTR does 
contain a functional 4E response element which, in this assay, directs the eIF4E-
dependent nuclear export of the chimeric mRNA, and consequently enhanced 
luciferase expression when active eIF4E is present.  Note that, as well as promoting 
mRNA export, eIF4E also enhances the translation of a specific subset of mRNAs, 
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however the RNA elements involved in eIF4E-regulated initiation of translation are 
present in the 5’UTR (Mamane et al., 2007; von der Haar et al., 2004) and, combined 
with our previous finding that inhibition of MEKs has no transcript-selective effect on 
the association of HDM2 mRNA with polyribosomes, it is unlikely that the effects of 
the 3’UTR are through control of translation.   
 
We then examined the effect of inhibitors of eIF4E phosphorylation on the activity of 
the reporter gene constructs.  As shown in Figure 3bi, whilst U0126 inhibited HDM2-
P2 promoter activity, as we have shown previously (Phelps et al., 2005), in the 
absence of the HDM2 3’UTR eIF4E over-expression did not confer any additional 
sensitivity to inhibition of MEKs or MNK1.  In contrast, the eIF4E-induced increase 
in activity of the hdm2luc01 3’UTR vector was ablated by both kinase inhibitors 
(Figure 3bii).  Therefore eIF4E-dependent export of HDM2 mRNA to the cytoplasm 
is dependent upon the activity of both MEK and MNK1 kinases, consistent with the 
known role of phosphorylation of eIF4E in its regulation of mRNA export 
(Topisirovic et al., 2004).  
 
Activation of growth factor-dependent signalling cascades results in the up-regulation 
of p53-activating signalling pathways (Harvey et al., 1993).  In the absence of 
sufficient activity of its negative-regulatory partner, HDM2, growth factor-stimulated 
cells will therefore cease proliferating due to the activation of p53-dependent cell 
cycle arrest or pro-apoptotic pathways (Blaydes and Wynford-Thomas, 1998).  The 
co-ordinated increase in expression of HDM2 in response to the same stimuli is 
therefore critical in maintaining the dynamic equilibrium of the p53-HDM2 auto-
regulatory feedback loop.  We have previously identified a MEK-dependent mRNA 
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export pathway as an important component of this regulation in cancer cell lines 
(Phelps et al., 2005), and now identify MNK1 and eIF4E as downstream effectors of 
MEKs that promote HDM2 mRNA export.  Our finding that the 3’UTR of HDM2 is 
sufficient to render it sensitive to this export pathway is consistent with the prior 
identification of eIF4E sensitivity elements that interact with eIF4E in the 3’UTRs of 
other mRNAs, notably CYCLIN D1 (Culjkovic et al., 2005; Culjkovic et al., 2006), 
and also our finding that both HDM2-P1 and P2 mRNA transcripts, which differ in 
their 5’UTRs, but contain a common coding sequence and 3’UTR, can both be 
exported through a MEK-dependent pathway.  Relatively minor perturbations in the 
normal regulation of HDM2 protein synthesis is sufficient to promote tumour 
development (Bond et al., 2004).  eIF4E is over-expressed in tumours including a 
majority of breast carcinomas, and is a known oncogene (Mamane et al., 2004).  Its 
oncogenic properties are believed to be attributable, at least in part, to its role in 
mRNA-selective nuclear export pathways (Topisirovic et al., 2003; Topisirovic et al., 
2004).  It seems highly probable that the ability of eIF4E to promote the production of 
the p53 antagonist, HDM2, will be an important contributor to the abnormal 
proliferation of these tumour cells. 
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LEGENDS TO FIGURES 
 
Figure 1.  Over-expression of eIF4E increases nuclear export of HDM2 transcripts.  
(a) MCF-7 cells in 6-well plates were transfected using Lipofectamine 2000 
(Invitrogen, Paisley, UK) with 0 to 2 μg of eIF4E expression vector pMV7-4E.  DNA 
in all transfections was kept constant using empty vector pMV7.  48 h post-
transfection, western blotting was performed using the following antibodies; HDM2 
(monoclonal antibody 2A9 (Chen et al., 1993)), Cyclin D1 (Calbiochem, La Jolla, 
CA, USA), eIF4E (BD Biosciences, Oxford, UK), rabbit anti β–actin antibody (Sigma 
Aldrich Co., Poole, UK).  (b) MCF-7 cells in 100 mm plates were transfected with 18 
μg pMV7 or pMV7-4E 48 h before cellular fractionation by hypotonic lysis (Phillips 
et al., 2006a).  Following RNA extraction using RNABee (Biogenesis Inc.), cDNA 
was synthesised using Superscript II reverse transcriptase (Invitrogen) and Taqman 
quantitative PCR analysis was performed using Taqman Universal PCR Mastermix 
(Applied Biosystems).  CYCLIN D1 transcripts were detected using a pre-designed 
 16
Taqman gene expression assay (Applied Biosystems) and HDM2 transcripts were 
determined as described previously (Phelps et al., 2005).  Data are normalised to 
GAPDH.  Results are expressed as percentage of transcripts in pMV7-transfected 
fraction.  Black bars, total cell; white bars, nuclear fraction; grey bars, cytoplasmic 
fraction.  Data is representative of three independent experiments.  Error bars are 
S.E.M. of triplicate PCR assays.  Asterisks indicate the significance of the change in 
transcript abundance in the subcellular fraction, compared to the total cell fraction 
(*p<0.05, **p<0.01, ***p<0.001. Unpaired, two-tailed Students t test).  Compared to 
pMV7-transfected controls, GAPDH levels in pMV7-4E transfected cells were 118.8 
± 6.57, 80.8 ± 6.88 and 76.0 ± 7.28% in total, nuclear and cytoplasmic fractions 
respectively.  Cellular fractionation was validated using semi-quantitative RT-PCR 
for snRNA U6, scRNA Y4 and GAPDH as described previously (Phelps et al., 2005; 
Phillips et al., 2006a).  Two PCRs for each fraction are shown, with a threefold 
difference in the amount of input cDNA to confirm PCRs have not plateaued. 
 
Figure 2.  Inhibitors of eIF4E phosphorylation reduce HDM2 protein expression and 
inhibit nuclear export of HDM2 transcripts.  (a) MCF-7 and T47D cell lysates were 
analysed by Western blotting.  Phospho-Ser-209 eIF4E antibody was purchased from 
Cell Signaling Technology, Beverly, MA, USA.  Data is representative of four 
independent experiments.  (b) T47D cells were cultured for 24 h in the presence of 
0.1% DMSO vehicle control, 25 μM U0126 (Promega) or 20 μM MNK inhibitor 
(Calbiochem) before being analysed for expression of the indicated proteins.  
Quantification of blots from four independent experiments by densitometry 
demonstrates that, relative to controls, U0126 and the MNK inhibitor reduce 
phosphorylated eIF4E by 70.6 ± 2.6% and 92.8 ± 4.2% respectively, and HDM2 by 
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69.6 ± 4.0% and 66.6 ± 7.9%.  (c) T47D cells were cultured for 24 h in the presence 
of 0.1% DMSO or 20 μM MNK1 inhibitor before cellular fractionation by hypotonic 
lysis.  Transcript levels were determined by qPCR and presented as in Figure 1b.  
Results are expressed as percentage of transcripts in DMSO-treated fraction.  Black 
bars, total cell; white bars, nuclear fraction; grey bars, cytoplasmic fraction.  Data is 
representative of three independent experiments.  Error bars are S.E.M. of triplicate 
qPCR assays.  Compared to DMSO-treated controls GAPDH levels in MNK 
inhibitor-treated cells were 68.9 ± 8.09, 82.4 ± 4.60 and 80.0 ± 4.10% in total, nuclear 
and cytoplasmic fractions respectively.  Cellular fractionation was validated by PCR 
for snRNA U6, scRNA Y4 as in Figure 1b. 
 
Figure 3.  eIF4E-dependent HDM2 transport requires the HDM2 3’-UTR.  (a) MCF-7 
cells in 96-well plates were transfected with 120 ng hdm2luc01 (Phelps et al., 2003) 
or hdm2luc01-3’UTR (HDM2 3’UTR cloned by 3’RACE and ligated into Xba1 site 
3’ of the luciferase gene in hdm2luc01) and 80 ng pMV7 (solid bars) or pMV7-4E 
(open bars) 48 h before reporter gene activity was assayed and normalised to 
expression from a co-transfection Renilla luciferase expression plasmid.  Results are 
expressed as a percentage of activity in hdm2luc01- and pMV7-transfected cells 
(mean ± S.E.M.).  Data is pooled from three independent experiments containing 
duplicate transfections each (n=6).  (b) MCF-7 cells in 96-well plates were transfected 
with 120 ng hdm2luc01 (i) or hdm2luc01-3’UTR (ii) and 80 ng pMV7 (solid bars) or 
pMV7-4E (open bars), and 24 h later exposed to 0.1 % DMSO, 25 μM U0126 or 20 
μM MNK1 inhibitor for a further 24 h before reporter gene activity was assayed.  
Results are expressed as percentage of activity in DMSO-treated pMV7-transfected 
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cells (mean ± S.E.M.).  Data is pooled from two independent experiments containing 
duplicate transfections each (n=4). 
 
 
 



